No shortage of TB drugs in India, regular supply to states ensured: Govt

"Regular assessments are conducted to evaluate the stock positions at various levels, from central warehouses to peripheral health institutes," it said

Firms selling anti-TB medicines are now shifting focus to govt tender biz
The Ministry of Health and Family Welfare assures that significant efforts are in place to ensure the availability of these crucial anti-TB drugs
ANI
2 min read Last Updated : Dec 14 2023 | 6:56 AM IST

There is no shortage of anti-tuberculosis drugs in the country and there has been a regular supply of anti-TB drugs to all the states and UTs from the central level under the National TB Elimination Programme (NTEP), said an official release.

According to the release from the Ministry of Health and Family Welfare, "There is no shortage of anti-tuberculosis drugs in the country. There has been a regular supply of anti-TB drugs to all the states and UTs from the central level under the NTEP throughout the year."

"Regular assessments are conducted to evaluate the stock positions at various levels, from central warehouses to peripheral health institutes," it said.

Further, states and UTs have been provisioned with resources for local procurement in limited quantities as and when required to meet the emergent requirements.

The details of the stock positions of anti-tuberculosis drugs are as under: The year-wise details for demand and disbursement of tuberculosis drugs from 2019 to 2023, as per Indent and Release Orders, are placed at https://tbcindia.gov.in/showfile.php?lid=3721

Earlier this year, the Ministry of Health and Family Welfare issued a statement refuting recent media reports that suggest a shortage of anti-tuberculosis (TB) drugs in India and question the efficacy of these drugs under the NTEP.

The ministry had labelled these reports as vague and ill-informed, lacking specific information about the availability of anti-TB medicines in stock.

The Ministry of Health and Family Welfare assures that significant efforts are in place to ensure the availability of these crucial anti-TB drugs, with regular assessments conducted to evaluate stock positions at various levels, from central warehouses to peripheral health institutes.

Therefore, the media reports were deemed vague and ill-informed, not accurately reflecting the actual stock of anti-TB drugs in the country.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :drugsTuberculosis in IndiaTuberculosisIndian drug makersHealth Ministry

First Published: Dec 14 2023 | 6:54 AM IST

Next Story